Year: 2019

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following presentations in December:Evercore ISI 2nd Annual HealthCONxDate: Wednesday, December 4, 2019Presentation: 11:00 a.m. ETLocation: Boston, MAPiper Jaffray 31st Annual Healthcare ConferenceDate: Thursday, December 5, 2019Presentation: 2:00 p.m. ETLocation: New York, NYA live webcast of the events will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company’s website for...

TORONTO, Nov. 27, 2019 (GLOBE NEWSWIRE) — Cryptologic Inc. (“Cryptologic” or the “Company”) (CSE:CRY) today announces its financial results for the quarter ended September 30, 2019.  Selected financial information of the Company for the three month and nine month periods ended September 30, 2019 and 2018 and the year ended December 31, 2018 is set forth below:Cryptologic mined a total of 602.91 Bitcoin in the three months ended September 30, 2019, at an average price per Bitcoin for the quarter of $13,706.  The Company achieved an Adjusted EBITDA1 of $3.9 million, or $0.17 per outstanding share, resulting in an Adjusted EBITDA Margin1 of 44% for the three months ending September 30, 2019.  The Company’s cost of revenue, which includes electricity cost, contractors’ fees and general facility operating costs, but excludes non-cash...

THIS NEWS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. PERSONSLOS ANGELES and TORONTO, Nov. 27, 2019 (GLOBE NEWSWIRE) — Tinley Beverage Company Inc. is pleased to provide an update on its licensing, co-packing and corporate initiatives. Long Beach LicensingThe Company is delighted to report that the relevant regulatory bodies at the state level have indicated that the Company’s cannabis entity has satisfied requirements for receipt of a cannabis manufacturing license, pending satisfactory municipal approvals from the City of Long Beach.  The Company has completed tenant improvements requested by the municipality during its pre-inspections, most of which were related to electrical upgrades that are required for the Company’s purpose-built bottling line.  The Company expects electrical inspections for this equipment...

TORONTO, Nov. 27, 2019 (GLOBE NEWSWIRE) — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G) is proud to share a link to a CTV News article featuring Nexalogy’s work in the Canadian Federal Elections in coordination with our client, Defence Research and Development Canada (DRDC).Marshall Gunter, CEO and Jeffrey Stevens, President were interviewed by Nicole Bogart of CTV News on the work Nexalogy completed during the Canadian Federal Elections. Nicole has extensive experience in covering issues surrounding cybersecurity, artificial intelligence, and social media. Please click the link below to read the full article.https://www.ctvnews.ca/politics/foreign-actors-tried-to-influence-canadian-election-talk-but-did-they-succeed-1.4701228“Getting mainstream media attention on the work we are doing is a huge validation...

Declares Fourth Quarter 2019 Cash Dividend of $0.70 Per ShareIncrease Marks Sixth Increase in Cash Dividend Since Company’s Formation in 2013WYOMISSING, Pa., Nov. 27, 2019 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (the “Company”), announced today that its Board of Directors approved a 2.94 percent increase in the quarterly cash dividend to $0.70 per share of its common stock beginning with the dividend declared for the fourth quarter of 2019.  The dividend is payable on December 27, 2019 to shareholders of record on December 13, 2019.The increase in the quarterly cash dividend represents the sixth increase in the cash dividend since Gaming and Leisure Properties was formed in late 2013.  The new dividend rate represents a 34.6% increase over the Company’s first quarterly cash dividend payment which was...

CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced it will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019, at 11:20 a.m. ET at the Four Seasons Hotel, Boston.A live webcast of the presentation can be accessed at http://wsw.com/webcast/evercore4/cycn/. An archived replay of the webcast will be available for approximately 90 days following the presentation.About Cyclerion TherapeuticsCyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough...

Highlights:Re-launch of Phase III drilling under recently discovered Zones 5B4-5M4-5NE, which returned excellent results last June contributing to the Central Gold Corridor resources (FIGURE 1); Ongoing completion of the North and South Gold Corridor resource estimate for the Chimo Mine property (FIGURE 2); Planning is underway for Phase IV drilling on the periphery of Zone 6N1 (FIGURE 3)VAL-D’OR, Quebec, Nov. 27, 2019 (GLOBE NEWSWIRE) — Cartier Resources Inc. (TSX-V: ECR) (“Cartier”) announces that it has resumed Phase III drilling on the Chimo Mine property, located 45 km east of Val-d’Or. Two drills are currently exploring the geometric extensions of Zones 5B4-5M4-5NE gold discovery, that follow excellent results reported last June (5.6 g/t Au over 8.5 m including 9.9 g/t Au over 3.0 m and 8.3 g/t Au over 2.5...

Faits saillants :Redémarrage du forage de la Phase III sous les Zones 5B4-5M4-5NE, récemment découvertes, qui avaient livrées d’excellents résultats en juin dernier contribuant aux ressources du Couloir aurifère Central (FIGURE 1); Réalisation en cours de l’estimation des ressources des Couloirs aurifères Nord et Sud de la propriété Mine Chimo (FIGURE 2); Planification en cours du forage de la Phase IV en périphérie de la Zone 6N1 (FIGURE 3).VAL-D’OR, Québec, 27 nov. 2019 (GLOBE NEWSWIRE) — Ressources Cartier Inc. (TSX-V: ECR) (“Cartier”) annonce la reprise des forages de la Phase III sur la propriété Mine Chimo, située à 45 km à l’Est de Val-d’Or. Deux foreuses explorent actuellement les extensions géométriques des nouvelles Zones aurifères 5B4-5M4-5NE, suite aux excellents résultats de juin dernier (5,6 g/t Au sur 8,5 m...

VANCOUVER, British Columbia, Nov. 27, 2019 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms” or “PSF”), has secured a cannabis supply agreement with Alberta Gaming, Liquor & Cannabis (AGLC), to become an official supplier of recreational adult-use cannabis products to the province’s licensed private sector retailers including Alberta’s only legal online source for recreational cannabis (AlbertaCannabis.org). The AGLC is the wholesaler to private retailers and the only authorized online retailer in Alberta. Pure Sunfarms expects to deliver its first shipment of high-quality dried flower, inclusive of pre-rolls which are anticipated to enter Pure Sunfarms’...

– PDUFA date assigned is July 13, 2020 –– VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children –WEST CHESTER, Pa., Nov. 27, 2019 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company, today announced that its New Drug Application (NDA) for VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy for the treatment of molluscum contagiosum (molluscum), has been accepted for filing by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this NDA is July 13, 2020.“There are no FDA-approved...